Integrating radioembolization ( 90Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report

Andrew Kennedy*, Douglas Coldwell, Bruno Sangro, Harpreet Wasan, Riad Salem

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Liver-directed therapies for unresectable cancers in the liver are evolving with increased efficacy and decreasing toxicity. One of these approaches uses radioactive microspheres delivered to hepatic tumors via the hepatic artery system-radioembolization. Use of this therapy is rapidly increasing worldwide with over 20,000 patients treated thus far. Therefore, greater understanding of its potential and optimal positioning of this therapy in the multimodality management of cancers affecting the liver is needed. This task has been undertaken by a group of the most experienced clinicians in radioembolization from multiple disciplines involved in this therapy.

Original languageEnglish (US)
Pages (from-to)81-90
Number of pages10
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number1
DOIs
StatePublished - Feb 2012

Keywords

  • SIRT
  • Yttrium-90
  • chemoradiation
  • hepatic
  • metastases

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Integrating radioembolization ( <sup>90</sup>Y Microspheres) into current treatment options for liver tumors: Introduction to the international working group report'. Together they form a unique fingerprint.

Cite this